CY1111521T1 - Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων - Google Patents
Λοιμογονος συστηματικος καλυκοϊος αιλουροειδωνInfo
- Publication number
- CY1111521T1 CY1111521T1 CY20111100163T CY111100163T CY1111521T1 CY 1111521 T1 CY1111521 T1 CY 1111521T1 CY 20111100163 T CY20111100163 T CY 20111100163T CY 111100163 T CY111100163 T CY 111100163T CY 1111521 T1 CY1111521 T1 CY 1111521T1
- Authority
- CY
- Cyprus
- Prior art keywords
- calculous
- calculus
- fcv
- double system
- present
- Prior art date
Links
- 230000003053 immunization Effects 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 241000282324 Felis Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 230000002498 deadly effect Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε ένα εμβόλιο για την ανοσοποίηση κατά μίας ιικής μολύνσεως προκαλούμενης από λοιμογόνο συστηματικό καλυκοϊό των αιλουροειδών (VS-FCV), μία νέα, άτυπη και ασυνήθιστα λοιμογόνο μορφή καλυκοϊού που καταλήγει σε ιδιαιτέρως μεταδοτικό και θανατηφόρο σύνδρομο αιμορραγικού πυρετού. Η παρούσα εφεύρεση περικλείει επιπλέον μεθόδους ανοσοποιήσεως των γατών έναντι συγκεκριμένων στελεχών του VS-FCV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/388,837 US7309495B2 (en) | 2003-03-14 | 2003-03-14 | Hemorrhagic feline calicivirus |
US10/769,531 US7264816B2 (en) | 2003-03-14 | 2004-01-30 | Virulent systemic feline calicivirus |
EP04720404A EP1606391B1 (en) | 2003-03-14 | 2004-03-12 | Virulent systemic feline calicivirus |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111521T1 true CY1111521T1 (el) | 2014-02-12 |
Family
ID=32962139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100163T CY1111521T1 (el) | 2003-03-14 | 2011-02-11 | Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων |
Country Status (10)
Country | Link |
---|---|
US (3) | US7309495B2 (el) |
EP (1) | EP2301574A1 (el) |
JP (1) | JP4724112B2 (el) |
AT (1) | ATE495758T1 (el) |
CY (1) | CY1111521T1 (el) |
DE (1) | DE602004031092D1 (el) |
DK (1) | DK1606391T3 (el) |
ES (1) | ES2358798T3 (el) |
NZ (1) | NZ541449A (el) |
PT (1) | PT1606391E (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7306807B2 (en) | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
GB0603749D0 (en) * | 2006-02-24 | 2006-04-05 | Moving Sun Ltd | Immune system stimulant and process of manufacturing the same |
WO2008150404A1 (en) * | 2007-05-30 | 2008-12-11 | Wyeth | Raccoon poxvirus expressing genes of feline antigens |
US10188725B2 (en) | 2015-12-14 | 2019-01-29 | Elanco Us Inc. | Hybrid core feline vaccines |
RU2628096C1 (ru) * | 2016-06-01 | 2017-08-14 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Штамм Эшли вируса калицивироза кошек для изучения противовирусной активности препаратов в отношении калицивироза кошек |
US11311616B2 (en) | 2017-11-06 | 2022-04-26 | Intervet Inc. | Feline leukemia virus vaccine |
WO2019115090A1 (en) | 2017-12-15 | 2019-06-20 | Intervet International B.V. | Multivalent feline vaccine |
US11167027B2 (en) | 2017-11-06 | 2021-11-09 | Intervet Inc. | Multivalent feline vaccine |
AU2018380582A1 (en) | 2017-12-08 | 2020-05-07 | Intervet International B.V. | Feline calicivirus vaccine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3937812A (en) * | 1974-11-21 | 1976-02-10 | Pitman-Moore, Inc. | Feline calicivirus vaccine and production thereof |
US3944469A (en) * | 1974-11-21 | 1976-03-16 | Pitman-Moore, Inc. | Feline calicivirus vaccine and production thereof |
US3992520A (en) * | 1974-11-27 | 1976-11-16 | Merck & Co., Inc. | Anti-fertility vaccine comprising solubilized zona pellucida and anti-serum |
US4522810A (en) * | 1982-12-09 | 1985-06-11 | The Regents Of The University Of California | Feline calicivirus vaccine |
US4795634A (en) * | 1986-03-14 | 1989-01-03 | Aphton Corporation | Method for contraception by immunization against the zona pellucida |
US5641487A (en) * | 1989-06-12 | 1997-06-24 | The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services | Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides |
US5716822A (en) * | 1989-07-21 | 1998-02-10 | Pharmacia & Upjohn Company | Feline calicivirus capsid gene and protein |
CA2090515C (en) * | 1992-02-28 | 2002-10-29 | Kazuhiko Kimachi | Anti-feline calicivirus recombinant antibody and gene fragment encoding the same |
CA2127531A1 (en) * | 1992-11-09 | 1994-05-26 | Zonagen, Inc. | Materials and methods for immunocontraception |
US6231863B1 (en) * | 1997-06-10 | 2001-05-15 | American Cyanamid Company | DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same |
US6355246B1 (en) * | 1999-06-10 | 2002-03-12 | Board Of Trustees Of Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
-
2003
- 2003-03-14 US US10/388,837 patent/US7309495B2/en active Active
-
2004
- 2004-01-30 US US10/769,531 patent/US7264816B2/en not_active Expired - Lifetime
- 2004-03-12 PT PT04720404T patent/PT1606391E/pt unknown
- 2004-03-12 DK DK04720404.5T patent/DK1606391T3/da active
- 2004-03-12 NZ NZ541449A patent/NZ541449A/en not_active IP Right Cessation
- 2004-03-12 EP EP10176944A patent/EP2301574A1/en not_active Withdrawn
- 2004-03-12 JP JP2006507137A patent/JP4724112B2/ja not_active Expired - Lifetime
- 2004-03-12 ES ES04720404T patent/ES2358798T3/es not_active Expired - Lifetime
- 2004-03-12 AT AT04720404T patent/ATE495758T1/de active
- 2004-03-12 DE DE602004031092T patent/DE602004031092D1/de not_active Expired - Lifetime
-
2007
- 2007-11-13 US US11/939,480 patent/US7449323B2/en not_active Expired - Lifetime
-
2011
- 2011-02-11 CY CY20111100163T patent/CY1111521T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE602004031092D1 (de) | 2011-03-03 |
ES2358798T3 (es) | 2011-05-13 |
US7264816B2 (en) | 2007-09-04 |
US7449323B2 (en) | 2008-11-11 |
JP2006524503A (ja) | 2006-11-02 |
US20080063663A1 (en) | 2008-03-13 |
JP4724112B2 (ja) | 2011-07-13 |
EP2301574A1 (en) | 2011-03-30 |
ATE495758T1 (de) | 2011-02-15 |
US20040259225A1 (en) | 2004-12-23 |
US7309495B2 (en) | 2007-12-18 |
DK1606391T3 (da) | 2011-03-21 |
US20040180064A1 (en) | 2004-09-16 |
PT1606391E (pt) | 2011-04-01 |
NZ541449A (en) | 2009-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111521T1 (el) | Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων | |
ATE542829T1 (de) | Impfstoff | |
CY1112901T1 (el) | Αιμορραγικος καλυκοϊος αιλουροειδων, εμβολιο καλυκοϊου και μεθοδος για προληψη μολυνσης και ασθενειας απο καλυκοϊο | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
CY1111552T1 (el) | Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | |
CY1113546T1 (el) | Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων | |
ATE451119T1 (de) | Untereinheit-impfstoff gegen das respiratorische synzytialvirus | |
DE60110822D1 (de) | Zubereitung zur immunisierung gegen den aids-virus | |
DK1409692T3 (da) | Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine | |
DE602004029657D1 (de) | Verbesserte impfstoffe | |
DK1881845T3 (da) | Nipah-virusvacciner | |
CY1113540T1 (el) | Εμβολια γριππης σκυλων | |
EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
AR047581A1 (es) | Vacunas de calicivirus felino | |
EA200700496A1 (ru) | Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита | |
DK1471936T3 (da) | HIV-Vaccine og fremgangsmåde til anvendelse | |
ATE507286T1 (de) | Immunisierung von fischen gegen virusinfektion | |
ATE310008T1 (de) | Immunologische adjuvans verbindungen | |
ATE372129T1 (de) | Impfstoff von umhüllten viren und verfahren zu seiner herstellung | |
DK1657248T3 (da) | Vaccine til forebyggelse og behandling af svine-progressiv atrofisk rhinitis | |
CL2010001175A1 (es) | Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv). | |
EA200301151A1 (ru) | Вакцина против натуральной оспы | |
DE602004023196D1 (de) | Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird) | |
ES2059305T5 (es) | Proteina del virus de la seudorrabia. |